About tlcr

Manuscript Submission

AME Editing Service

Reprint & Permission

Advertising

Contact us

Focused Issues more

Vol 7, No 5 (October 2018): Malignant Pleural and Peritoneal Mesothelioma-Guest Editors: Paul Van... More >>
Vol 7, No 4 (August 2018): Lung Cancer in Never Smokers-Guest Editor: Adi F. Gazdar More >>
Vol 7, No 3 (June 2018): Lung Cancer Screening-Guest Editors: Caroline Chiles, Reginald F. Munden More >>

Sponsored by

Translational Lung Cancer Research is sponsored by Nanjing General Hospital of Nanjing Military Command, Nanjing, China

Sponsored by

Original Article

A scalable solution for tumor mutational burden from formalinfixed, paraffin-embedded samples using the Oncomine Tumor Mutation Load Assay
Ruchi Chaudhary, Luca Quagliata, Jermann Philip Martin, Ilaria Alborelli, Dinesh Cyanam, Vinay Mittal, Warren Tom, Janice Au-Young, Seth Sadis, Fiona Hyland

Review Article

Tumor mutational burden assessment as a predictive biomarker for immunotherapy in lung cancer patients: getting ready for prime-time or not?
Simon Heeke, Paul Hofman
The clinical utility of tumor mutational burden in non-small cell lung cancer
Laurent Greillier, Pascale Tomasini, Fabrice Barlesi
Clinical utility of tumor mutational burden in patients with nonsmall cell lung cancer treated with immunotherapy
Lizza E. Hendriks, Etienne Rouleau, Benjamin Besse
Methods of measurement for tumor mutational burden in tumor tissue
Bárbara Meléndez, Claude Van Campenhout, Sandrine Rorive, Myriam Remmelink, Isabelle Salmon, Nicky D’Haene
Measuring tumor mutation burden in non-small cell lung cancer: tissue versus liquid biopsy
Francesca Fenizia, Raffaella Pasquale, Cristin Roma, Francesca Bergantino, Alessia Iannaccone, Nicola Normanno
Approach to evaluating tumor mutational burden in routine clinical practice
John Truesdell, Vincent A. Miller, David Fabrizio
Predictive markers for anti-PD-1/PD-L1 therapy in non-small cell lung cancer—where are we?
Matthew Evans, Brendan O’Sullivan, Matthew Smith, Philippe Taniere
Challenges and unanswered questions for the next decade of immune-oncology research in NSCLC
Niki Karachaliou, Manuel Fernandez-Bruno, Jillian Wilhelmina Paulina Bracht, Rafael Rosell
Implementing tumor mutational burden (TMB) analysis in routine diagnostics—a primer for molecular pathologists and clinicians
Michael Allgäuer, Jan Budczies, Petros Christopoulos, Volker Endris, Amelie Lier, Eugen Rempel, Anna-Lena Volckmar, Martina Kirchner, Moritz von Winterfeld, Jonas Leichsenring, Olaf Neumann, Stefan Fröhling, Roland Penzel, Michael Thomas, Peter Schirmacher, Albrecht Stenzinger

Review Article

Targeted therapy for non-small cell lung cancer: current standards and the promise of the future
Bryan A. Chan, Brett G.M. Hughes
Global trends of lung cancer mortality and smoking prevalence
Farhad Islami, Lindsey A. Torre, Ahmedin Jemal
Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations—a review
Erin L. Stewart, Samuel Zhixing Tan, Geoffrey Liu, Ming-Sound Tsao
Circulating tumor cells versus circulating tumor DNA in lung cancer—which one will win?
Silvia Calabuig-Fariñas, Eloísa Jantus-Lewintre, Alejandro Herreros-Pomares, Carlos Camps

Review Article

Tackling ALK in non-small cell lung cancer: the role of novel inhibitors
Francesco Facchinetti, Marcello Tiseo, Massimo Di Maio, Paolo Graziano, Emilio Bria, Giulio Rossi, Silvia Novello

Review Article

Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer
Takashi Kohno, Takashi Nakaoku, Koji Tsuta, Katsuya Tsuchihara, Shingo Matsumoto, Kiyotaka Yoh, Koichi Goto

Review Article on Lung Cancer Diagnostics and Treatments 2015: A Renaissance of Patient Care

Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities
Jeryl Villadolid, Asim Amin

Original Article

Prognostic value of Twist in lung cancer: systematic review and meta-analysis
Junli Zeng, Ping Zhan, Guannan Wu, Wen Yang, Wenjun Liang, Tangfeng Lv, Yong Song
The suitability of small biopsy and cytology specimens for EGFR and other mutation testing in non-small cell lung cancer
Shu Wang, Bing Yu, Chiu Chin Ng, Belinda Mercorella, Christina I. Selinger, Sandra A. O’Toole, Wendy A. Cooper
Itraconazole can inhibit malignant pleural effusion by suppressing lymphangiogenesis in mice
Yunfen Wang, Yanwen Yao, Hongbin Liu, Xingqun Ma, Tangfeng Lv, Dongmei Yuan, Xinwu Xiao, Jie Yin, Yong Song
Ratio of maximum standardized uptake value to primary tumor size is a prognostic factor in patients with advanced non-small cell lung cancer
Fangfang Chen, Yanwen Yao, Chunyan Ma, Xingqun Ma, Zhaofeng Wang, Tangfeng Lv, Xinwu Xiao, Jie Yin, Yong Song
Advanced proton beam dosimetry part II: Monte Carlo vs. pencil beam-based planning for lung cancer
Dominic Maes, Jatinder Saini, Jing Zeng, Ramesh Rengan, Tony Wong, Stephen R. Bowen
The use of TCP based EUD to rank and compare lung radiotherapy plans: in-silico study to evaluate the correlation between TCP with physical quality indices
Abdulhamid Chaikh, Jacques Balosso

Original Article

BRAF mutations in non-small cell lung cancer
Peter P. Luk, Bing Yu, Chiu Chin Ng, Belinda Mercorella, Christina Selinger, Trina Lum, Steven Kao, Sandra A. O’Toole, Wendy A. Cooper
The cytokinesis-blocked micronucleus assay as a novel biomarker for selection of lung cancer screening participants
Randa A. El-Zein, Carol J. Etzel, Reginald F. Munden

Review Article

Neoadjuvant and adjuvant epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer
Haoran Zhai, Wenzhao Zhong, Xuening Yang, Yi-Long Wu
Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations—a review
Erin L. Stewart, Samuel Zhixing Tan, Geoffrey Liu, Ming-Sound Tsao
Clinical trials for lung cancer in China
Fei-Yu Niu, Wen-Zhao Zhong, Qing Zhou, Yi-Long Wu
Recurrence after surgery in patients with NSCLC
Hidetaka Uramoto, Fumihiro Tanaka
Prognostic markers in lung cancer: is it ready for prime time?
Chang-Qi Zhu, Ming-Sound Tsao
Potential biomarkers for lung cancer screening
Gabriella Sozzi, Mattia Boeri
Particle therapy in non-small cell lung cancer
Zhongxing Liao, Charles B. Simone II
Computer Aided Nodule Analysis and Risk Yield (CANARY) characterization of adenocarcinoma: radiologic biopsy, risk stratification and future directions
Ryan Clay, Srinivasan Rajagopalan, Ronald Karwoski, Fabien Maldonado, Tobias Peikert, Brian Bartholmai
Immunotherapy and radiation therapy for operable early stage and locally advanced non-small cell lung cancer
Neil K. Taunk, Andreas Rimner, Melissa Culligan, Joseph S. Friedberg, Julie Brahmer, Jamie Chaft
Combining immunotherapy and radiation therapy for small cell lung cancer and thymic tumors
Suchit H. Patel, Andreas Rimner, Roger B. Cohen
Intraoperative near-infrared imaging of mesothelioma
Gregory Thomas Kennedy, Andrew Newton, Jarrod Predina, Sunil Singhal
BAP1, a tumor suppressor gene driving malignant mesothelioma
Mitchell Cheung, Joseph R. Testa
Uncovering the immune tumor microenvironment in non-small cell lung cancer to understand response rates to checkpoint blockade and radiation
Jonathan E. Schoenhals, Steven N. Seyedin, Clark Anderson, Eric D. Brooks, Yun R. Li, Ahmed I. Younes, Sharareh Niknam, Ailin Li, Hampartsoum B. Barsoumian, Maria Angelica Cortez, James W. Welsh
Diagnostic and prognostic biomarkers for malignant mesothelioma: an update
Zhongjian Chen, Giovanni Gaudino, Harvey I. Pass, Michele Carbone, Haining Yang
Immunotherapy for malignant pleural mesothelioma: current status and future directions
Jordan Dozier, Hua Zheng, Prasad S. Adusumilli
Biology and clinical significance of circulating tumor cell subpopulations in lung cancer
Linda O’Flaherty, Harriet Wikman, Klaus Pantel
Routine clinical use of circulating tumor cells for diagnosis of mutations and chromosomal rearrangements in non-small cell lung cancer—ready for prime-time?
Emma Pailler, Vincent Faugeroux, Marianne Oulhen, Cyril Catelain, Françoise Farace
Challenges and unanswered questions for the next decade of circulating tumour cell research in lung cancer
Sumitra Mohan, Francesca Chemi, Ged Brady
Biophysical technologies for understanding circulating tumor cell biology and metastasis
Derrick W. Su, Jorge Nieva
Clinical utility of circulating tumor cells in patients with non-small-cell lung cancer
Marianna Gallo, Antonella De Luca, Monica Rosaria Maiello, Amelia D’Alessio, Claudia Esposito, Nicoletta Chicchinelli, Laura Forgione, Maria Carmela Piccirillo, Gaetano Rocco, Alessandro Morabito, Gerardo Botti, Nicola Normanno
Integrating immunotherapy into chemoradiation regimens for medically inoperable locally advanced non-small cell lung cancer
Salma K. Jabbour, Abigail T. Berman, Charles B. Simone II

Review Article

Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer
Takashi Kohno, Takashi Nakaoku, Koji Tsuta, Katsuya Tsuchihara, Shingo Matsumoto, Kiyotaka Yoh, Koichi Goto
Overview of clinicopathologic features of ALK-rearranged lung adenocarcinoma and current diagnostic testing for ALK rearrangement
Hyojin Kim, Jin-Haeng Chung

Systematic Review and Meta-analysis

Association of the metformin with the risk of lung cancer: a meta-analysis
Li Wang, Yong Song, Guan-Nan Wu, Dong-Mei Yuan

Editorials

Dulanermin in cancer therapy: Still much to do
Cristina Quintavalle, Gerolama Condorelli

Review Articles

EGFR molecular testing in African-American non-small cell lung cancer patients - a review of discrepant data
Bradley T. Clifford, Pingfu Fu, Nathan A. Pennell, Balazs Halmos, Rom S. Leidner
Copy number gains of FGFR1 and 3q chromosome in squamous cell carcinoma of the lung
Pedro Mendez, Jose Luis Ramirez
Role of HGF/MET axis in resistance of lung cancer to contemporary management
Kanwal Pratap Singh Raghav, Ana Maria Gonzalez-Angulo, George R. Blumenschein Jr
Circulating soluble intercellular adhesion Molecule-1 in lung cancer: a systematic review
Xiaoling Gu, Chunyan Ma, Dongmei Yuan, Yong Song

Onartuzumab plus erlotinib

Targeting MET in NSCLC: looking for a needle in a haystack
Lorenza Landi, Federico Cappuzzo

Review Article on Update on Pathology and Predictive Biomarkers of Lung Cancer

Biology of invasive mucinous adenocarcinoma of the lung
Yoon Jin Cha, Hyo Sup Shim
Immunohistochemistry for predictive biomarkers in non-small cell lung cancer
Mari Mino- Kenudson

Below are the latest Translational Lung Cancer Research articles published online ahead of print publication.

Original Article



Editorial




Brief Report